Dr. Daniel Petro
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 272
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Jefferson Medical College of Thomas Jefferson University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
PA license MD423344
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UPMC Presbyterian Shadyside Pittsburgh, PA
- Magee Womens Hospital of UPMC Health System Pittsburgh, PA
- UPMC PAssavant Pittsburgh, PA
- UPMC St Margaret Pittsburgh, PA
- UPMC Altoona Altoona, PA
Medical groups
- Oncology Hematology Association Inc (202 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 272
- Services billed
- 912
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 439 | 126 |
| Established patient office or other outpatient visit, 40-54 minutes | 290 | 88 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 147 | 47 |
| Hospital discharge day management, more than 30 minutes | 72 | 63 |
| New patient office or other outpatient visit, 60-74 minutes | 23 | 23 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 19 | 19 |
| Established patient office or other outpatient visit, 30-39 minutes | 18 | 16 |
| Established patient office or other outpatient visit, 20-29 minutes | 12 | 11 |
| Hospital discharge day management, 30 minutes or less | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tagrisso (osimertinib mesylate) | 33 |
| Mirtazapine Other prescribers in Pittsburgh, PA | 30 |
| Ondansetron Hcl Other prescribers in Pittsburgh, PA | 23 |
| Prednisone Other prescribers in Pittsburgh, PA | 19 |
| Lorbrena (lorlatinib) | 14 |
| Pantoprazole Sodium Other prescribers in Pittsburgh, PA | 13 |
| Imbruvica (ibrutinib) | 12 |
| Olanzapine Other prescribers in Pittsburgh, PA | 11 |
| Ibrance (palbociclib) | 11 |
| Eliquis (apixaban) Other prescribers in Pittsburgh, PA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 7 payments worth $464 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $411 |
|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20.46 |
| Beone Medicines USA, Inc. | $18.45 |
| Celgene Corporation | $13.48 |
| Food and Beverage | $185 |
|---|---|
| Consulting Fee | $168 |
| Education | $112 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jun 17, 2025 | Consulting Fee TAGRISSO · Oncology | $168 |
| AstraZeneca Pharmaceuticals LP Jul 30, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $68.49 |
| AstraZeneca Pharmaceuticals LP Nov 19, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.